Aptamers are isolated by a Systematic Evolution of Ligands by Exponential Enrichment process—specifically designed to identify sequences that undergo conformational changes upon target recognition. In this approach, a randomized oligonucleotide library is hybridized to a capture strand immobilized on a solid support. Target-bound sequences induce stem closure to be released from the capture strand. These sequences are then collected, amplified, and evolved through multiple rounds under gradually increasing selection pressures to ensure improved affinity and high selectivity for further adaptation into structure-switching biosensing platforms.

Electrochemical aptamer-based (E-AB) sensors leverage multiple advantages of electrochemical signaling and biological properties of aptamer. The sensors rely on a redox reporter-modified aptamer attached on a monolayer-coated gold electrode. Target binding induces a conformational change that alters electron transfer efficiency, which is readily monitored via electrochemical techniques. E-AB sensors can be miniaturized for direct deployment in complex biofluids, enabling real-time monitoring at sub-second resolution—a capability ideally suitable for tracking fast-acting or short-lived medications.

Cross-reactive sensor arrays utilize a suite of aptamers with broad specificities to identify and differentiate structurally analogous molecules. Instead of relying on a single-target signal, these arrays produce unique response patterns—or "molecular fingerprints"—that allow for multiplexed detection. The array-derived signaling patterns can then be deconvoluted by means of multivariate analysis, allowing for the discrimination of similar molecules in complex mixtures simultaneously.

High-throughput aptamer-based platforms integrate sensor arrays to rapidly characterize interactions within multi-drug panels. These systems facilitate the systematic, scalable analysis of drug–drug interactions, offering predictive insights crucial for managing polypharmacy—the concurrent administration of multiple therapeutic agents. Unlike conventional screening methods such as high-performance liquid chromatography or cell-based assays, these arrays provide a more efficient and cost-effective methodology for evaluating molecular behavior within complex therapeutic regimens.